

Author's response to reviews

Title: Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study

Authors:

Rieke Alten (rieke.alten@schlosspark-klinik.de)
Juan Gomez-Reino (juan.gomez-reino.carnota@sergas.es)
Patrick Durez (Patrick.durez@ruma.ucl.ac.be)
Andre Beaulieu (ab5@videotron.ca)
Anthony Sebba (asebba@tampabay.rr.com)
Gerhard Krammer (gerhard.krammer@novartis.com)
Ralph Preiss (ralph.preiss@novartis.com)
Udayasankar Arulmani (udayasankar.arulmani@novartis.com)
Albert Widmer (albert.widmer@novartis.com)
Xavier Gitton (xavier.gitton@novartis.com)
Herbert Kellner (hk@prof-dr-kellner.de)

Version: 7 Date: 5 July 2011

Author's response to reviews:

Dear Editor,

we performed the corrections as required:

1. abstract: trial registration is no more a title heading
2. all highlighting and tracking is removed from the manuscript, we submit the clean version
3. we removed all visible vertical lines from our tables
4. the email addresses of all authors are included on the title page in the requested format
5. we checked the manuscript for typographical errors and made the appropriate corrections.

Best regards and thank you

Rieke Alten